Antipsychotics learning module

6. Further information

British National Formulary—available online

Martindale: the complete drug reference—available online

NICE. Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care – clinical guideline 82 (issued March 2009)

Barnes TRE, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567–620

Information from MHRA

Note. References to older MHRA advice is included for background only; the information will have been incorporated into summaries of product characteristics and some will have been superseded.

Source Article title Comment
Drug Safety Update September 2011 Antipsychotics: use during third trimester of pregnancy and extrapyramidal effects or withdrawal symptoms in newborns Risk of extrapyramidal effects and withdrawal  effects in newborns born to mothers on antipsychotics during the third trimester
Drug Safety Update April 2011 Atypical (second-generation) antipsychotics: reminder to monitor and manage weight, glucose, and lipid levels  
MHRA website March 2010 Antipsychotic drugs Uses of antipsychotics, mechanism of action, side-effects and use in elderly people with dementia
Drug Safety Update June 2009 Antipsychotics: risk of venous thromboembolic events Before and during treatment with antipsychotics, risk factors for venous thromboembolism should be identified and addressed
Drug Safety Update March 2009 Antipsychotics: use in elderly people with dementia Antipsychotics may increase risk of stroke and slightly increase risk of early death in the elderly
Pharmacovigilance Working Party assessment report Antipsychotics and cerebrovascular accident Basis for the introduction of warning on cardiovascular adverse events into summaries of product characteristics

Page 39 of 46

Page last modified: 03 October 2018